Screening for Latent Tuberculosis Infection in Patients with Autoimmune Diseases Before Initiating TNF-α Inhibitors Therapy

Dimitra Perifanou, Daniil Zoe, Efthimia Petinaki, Konstantinos Konstantinou, Konstantinos Gourgoulianis

ABSTRACT

Introduction: QFT-GIT is more sensitive than TST in patients under immunosuppressive therapy, but TST detects more cases of LTBI. TST remains an inexpensive test worldwide, which does not need laboratory equipment. Material and Methods: Overall, 457 patients having autoimmune diseases were referred. Of those referred, 158 patients were screened with QFT-GIT and TST. No patient in the present study was known to be HIV positive, or had a history of tuberculosis contact the last year. Additionally, neither of the two methods distinguish latent from active TB, and neither one is better at recognizing patients with autoimmune diseases who could avail from preventive chemoprophylaxis. Results: QFT-GIT is more sensitive than TST in patients under immunosuppressive therapy, but TST detects more cases of LTBI. TST remains an inexpensive test worldwide, which does not need laboratory equipment. Conclusion: Since the literature for the economic evaluation of LTBI screening has not clearly defined which test is ultimately more cost-effective, low income countries like Greece should continue using TST as the primary method for diagnosis of LTBI. Keywords: LTBI, autoimmune disease, TNF.

1. INTRODUCTION

Mycobacterium Tuberculosis (MTB) is the causative agent of tuberculosis. According to WHO, one-third of the global population is infected with MTB but doesn’t transmit the disease (1). People with latent tuberculosis infection (LTBI) represent a large population with the potential for disease reactivation. The key point to controlling TB is systematic testing and treatment, thus targeted strategies for the protection of public health involves identifying people with latent infection, especially those at high risk of developing TB, such as patients with inflammatory autoimmune diseases (1).

Tumor necrosis factor TNFα is a pro-inflammatory cytokine which plays an important role in pathogenesis of several autoimmune disorders, and the immune response of MTB infection (2).

The introduction of TNFα inhibitor treatment of autoimmune diseases improved the everyday routines of patients. However, an increased risk of developing serious infections, including tuberculosis, was revealed (3). Screening for the diagnosis of suspected LT or TB infection should include detailed medical history of exposure to MTB (previous history or close contact to active TB within the last year). Screening typically consists of Tuberculin Skin Test (TST) administration and evaluation after 48/72 hours and/or blood sampling for Quantiferon Tb Gold In-Tube (QFT-GIT), chest x-ray, (4, 3) and clinical history of active TB symptoms. TST has poor specificity in particular population groups, including BCG vaccinated and those who have been exposed to NonTuberculosis Mycobacteria (NTM). Moreover TST may show a false negative result in patients under immunosuppressive treatment (5).

In the last 15 years a new, in-vitro diagnostic method has been developed. QFT-GIT [Cellestis Limited, Carnegie Australia] which measures the interferon-γ (INF–γ) in peripheral blood after affection of specific proteins ESAT-6, CFP-10 and TB7.7 in stimulated T-cells. This method has been shown to be more specific for the detection of MTB than TST, as it’s not affected by BCG vaccination or other environmental mycobacterium (6, 7).

2. AIM

The study aim was to compare the usefulness of the two tests in diagnosis of LTBI, in patients with autoimmune diseases considering initiation of therapy with TNF-α inhibitors.
3. SUBJECTS AND METHODS

The study was conducted at an Outpatient Tuberculosis Department of the General Pulmonary Disease Hospital of Athens “SOTIRIA” between 01/01/2008 and 31/12/2011. All patients included in the study received a medical referral to the outpatient clinic from a Rheumatologist, Dermatologist or Gastroenterologist. Demographic information, medical history, etiology for visiting the clinic, history of TB infection or exposure to MTB, therapy for LTBI or TB infection in the past and immunosuppressive treatment were recorded from the medical patient’s file. Overall, 457 patients having autoimmune diseases were referred. Of those referred, 158 patients were screened with QFT-GIT and TST. No patient in the present study was known to be HIV positive, or had a history of tuberculosis contact the last year.

**Tuberculin Skin Test:** Mantoux tests were evaluated after 48-72 hours by trained health care professionals. A negative result was defined as a TST with a diameter ≤ 5mm of transverse induration (8).

**QuantiFERON-TB Gold In-Tube:** QFT-GIT tests were reported as positive when identifying the antigens ESAT-6, CFP-10, (> =35 IU/ml, and > 25% of Nil), as negative, if non discovery of antigens (< 0.35 OR ≥ 0.35 and < 25% of Nil) and indeterminate (< 0.35 OR ≥ 0.35 and < 25% of Nil) (9). QFT-GIT was performed simultaneously with TST.

**Chest x-ray:** A chest x-ray was given to all patients requesting pulmonary evaluation of previous inactive TB (calcified or noncalcified nodules or fibrotic lesions) according to published guidelines (10). The presence of LTBI was established by having TST(+) and/or QFT-GIT(+), and abnormal findings in the chest x-ray suggestive old TB.

**Therapies:** Chemoprophylaxis for LTBI with isoniazid for 9 months or isoniazid for 6 months and isoniazid plus rifampicin for 3-4 months was administered to patients with TST(+) or QFT-GIT(+) in conjunction with findings on chest x-ray suggestive of previously treated TB (11). Drug therapies for autoimmune diseases were classified into corticosteroids, Disease Modifying Anti-Rheumatic Drugs (DMARDs) including methotrexate, azathioprine, and TNF α inhibitors (infliximab, etanercept or adalimumab). The study protocol was approved by the committee of School of Medicine of the University of Thessaly.

**Statistical analysis**

Quantitative variables were expressed as mean values with standard deviation (SD), while qualitative variables were expressed as absolute and relative frequencies. For the comparison of proportions chi-square and Fisher’s exact tests were used. Logistic regression analysis in a stepwise method (p for entry 0.05, p for removal 0.10) was used in order to find independent factors associated with TST(+), QFT-GIT tests and abnormal x-ray. Adjusted odds ratios (OR) with 95% confidence intervals (95% CI) were calculated from the results of the logistic regression analyses. All reported p-values are two-tailed. Statistical significance was set at p<0.05.

Analyses were conducted using SPSS statistical software (SPSS Inc. Released 2009. PASW Statistics for Windows, Version 18.0. Chicago: SPSS Inc.). Kappa values (κ) were calculated to assess the agreement between TST and QFT-GIT results. Kappa values were defined as: values ≤ 0 indicate no agreement, 0.01-0.20 none to slight, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 substantial, and 0.81-1.00 almost perfect agreement.

4. RESULTS

The study group characteristics are summarized in Table 1. 158 patients underwent both TST and QFT-GIT. 94.9% (n=150) were born in Greece, 52.5% (n=83) were male, mean age (years) mean (SD) 49.4 (15.8).

| Diagnosis                        | N (%)   |
|---------------------------------|---------|
| Rheumatoid arthritis            | 58 (36.7) |
| Psoriasis / psoriasis arthritis | 67 (42.4) |
| Spondylitis arthritis           | 19 (12.0) |
| Inflammatory bowel diseases     | 7 (4.4)  |

Table 1. Sample characteristics. 1)Other autoimmune disease=Sjögren’s syndrome, systemic lupus erythematosus, vasculitis, sclerosis; 2)DMARDs = Disease Modifying Anti-Rheumatic Drugs; 3)Other= Nonsteroidal Anti-inflammatory Drugs (NSAIDs), vitamins, antibiotics; 4)LTBI= latent tuberculosis infection; 5)Other: Didn’t appear to the appointment (n=11, 7.0%); Didn’t seek for medical advice (n=12, 7.6%); 6) Other = Isoniazid+Rifampicin+Ethabutole, Ethambutol+Quinolone

48-72 hours by trained health care professionals. A negative result was defined as a TST with a diameter ≤ 5mm of transverse induration (8).
age 49.4 years (±15.8 years). The leading cause of reference was psoriasis and psoriatic arthritis (42.4%, n=67). 41.8% of patients (n=66) had other health issues for which they were receiving therapy and 10 patients (6.6%) declared that they had been infected of TB in the past, but not during last year.

Table 2 presents the rate of the tests (TST, QFT-GIT, chest x-ray) and the BCG vaccination status of 457 patients. In table 3, the proportion of QFT-GIT(+) screening was higher in patients with TST >15 mm (51.0%) and significantly higher in comparison to groups with TST of 6-10 mm (22.4%), 11-15 mm (18.4%) and negative (8.2%) diameter (p<0.001). Also, the proportion of QFT-GIT(+) was higher in BCG vaccinated patients compared to those who did not receive vaccination (p<0.001).

Table 1. TST, QFT-GIT and chest x-ray results of 457 patients. 1) Tuberculin Skin Test; 2) QuantiFERON®-TB Gold In-Tube Test; 3) Bacillus Calmette–Guérin Vaccin

A high rate of patients (66.7%) had LTBI on the basis of TST(+) and the absence of BCG immunization, and (31.0%) QFT-GIT(+). The high rate of positive results may be due to age, since the mean age of the study population was 49.4, and older participants had potentially been exposed to the tuberculosis mycobacterium during childhood. The prevalence of disease in Greece was very high (30 to 60/100,000) until the 1980s (12). TB incidence in Greece declined by 40% from 1980 to 2000 and continues to decline (13).

In regard to TST(+), another possible explanation is that BCG immunization was performed when children entered school (4-7 years old), according to the Greek National Vaccination Program. This would agree with the findings of Farhat et al. (14) and Wang et al. (15) showing that BCG vaccination in latter childhood has a much higher effect on TST results than vaccination performed during infancy. However, the effect of vaccination wanes after 10 years and TST’s reaction is usually moderate (14). Furthermore, when the study population is divided into 4 groups according to TST induration; negative, 6-10mm, 11-15mm and >15mm, we observed a high rate of positive results may be due to age, since the mean age of the study population was 49.4, and older participants had potentially been exposed to the tuberculosis mycobacterium during childhood.

Table 2. TST, QFT-GIT and chest x-ray results of 457 patients. 1) Tuberculin Skin Test; 2) QuantiFERON®-TB Gold In-Tube Test; 3) Bacillus Calmette–Guérin Vaccin

Table 3. QFT-GIT results associated with TST and BCG status. Pearson’s chi-square test

Kappa value (κ) equal to 0.43 (95% CI 0.18, 0.68) in cases of corticosteroids therapy. There was “slight” agreement in patients with rheumatoid arthritis (κ 0.20 (95% CI 0.01, 0.39)) and psoriasis (κ 0.18 (95% CI 0.07, 0.29)) and in BCG vaccinated (κ 0.04 (95% CI -0.04, 0.12)). No agreement between the two tests was shown in patients who received TNT-a therapy (κ -0.07, (95% CI-0.39, 0.24)) (Table 6).

5. DISCUSSION

A high rate of patients (66.7%) had LTBI on the basis of TST(+) and the absence of BCG immunization, and (31.0%) QFT-GIT(+). The high rate of positive results may be due to age, since the mean age of the study population was 49.4, and older participants had potentially been exposed to the tuberculosis mycobacterium during childhood. The prevalence of disease in Greece was very high (30 to 60/100,000) until the 1980s (12). TB incidence in Greece declined by 40% from 1980 to 2000 and continues to decline (13).

In regard to TST(+), another possible explanation is that BCG immunization was performed when children entered school (4-7 years old), according to the Greek National Vaccination Program. This would agree with the findings of Farhat et al. (14) and Wang et al. (15) showing that BCG vaccination in latter childhood has a much higher effect on TST results than vaccination performed during infancy. However, the effect of vaccination wanes after 10 years and TST’s reaction is usually moderate (14). Furthermore, when the study population is divided into 4 groups according to TST induration; negative, 6-10mm, 11-15mm and >15mm, we observed a high rate of QFT-GIT(+) results in TST(-) subgroup. Also a high rate of TST diameter >15mm had QFT-GIT(+) results, agreeing with Allet et al. (15,16) and suggesting that increased TST diameter >15 mm could indicate true LTBI (15). 45 cases were both (QFT-GIT(+)) and TST(+) and were strongly associated in multiple logistic regression. In 73 cases, four QFT-GIT(+)/TST(-) and 69 QFT-GIT(-)/TST(+) cases were discordant. This large difference in QFT-GIT(+) /TST(-) cases suggests that TST was able to detect LTBI almost as well as QFT-GIT. Regarding the four TST(-)/ QFT-GIT(+) discordant results, three had rheumatoid arthritis, one had Spondylitis arthritis mean age 75 had other health issues and agrees with Weinfurter et al. study (17). Furthermore...
# Screening for Latent Tuberculosis Infection in Patients with Autoimmune Diseases

## Table 4. Association of medical history, medical examination and use of immunosuppressive therapy with TST, QFT-GIT and Chest x-ray.

|                                            | Positive TST |                  | Positive QFT-GIT |                  | Abnormal Chest x-ray |                  |
|--------------------------------------------|--------------|------------------|-------------------|-------------------|----------------------|------------------|
|                                            | No (N=44)    | Yes (N=114)      | P*                | No (N=109)        | Yes (N=49)          | P*               |
|                                            | N (%)        | N (%)            |                   | N (%)             | N (%)               |                   |
| Age ≤49.4                                  | 16 (21.1)    | 60 (78.9)        | 0.067             | 64 (84.2)         | 12 (15.8)           | <0.001           |
|                                            | 28 (34.1)    | 54 (65.9)        |                   | 45 (54.9)         | 37 (45.1)           | 42 (76.4)        |
| Age >49.4                                  | 26 (34.7)    | 49 (65.3)        | 0.069             | 54 (72)           | 21 (28)             | 0.436            |
|                                            | 18 (21.7)    | 65 (78.3)        |                   | 55 (66.3)         | 28 (33.7)           | 49 (83.1)        |
| Sex Females                                |              |                  |                   |                   |                     |                  |
|                                            | 20 (34.5)    | 38 (65.5)        | 0.125**           | 40 (69)           | 18 (31)             | 0.562**          |
|                                            | 6 (31.6)     | 13 (68.4)        |                   | 14 (73.7)         | 5 (26.3)            | 12 (92.3)        |
| Sex Males                                  | 12 (17.9)    | 55 (82.1)        |                   | 46 (68.7)         | 21 (31.3)           | 38 (84.4)        |
| Diagnosis Rheumatoid arthritis             | 3 (42.9)     | 4 (57.1)         |                   | 6 (85.7)          | 1 (14.3)            | 5 (83.3)         |
| Diagnosis Spondylitis arthrits             |              |                  |                   |                   |                     |                  |
| Diagnosis Psoriasis / psoriatic arthritis   | 12 (17.9)    | 55 (82.1)        |                   | 46 (68.7)         | 21 (31.3)           | 38 (84.4)        |
| Diagnosis Inflammatory bowel diseases       | 14 (73.7)    | 5 (26.3)         |                   | 12 (92.3)         | 1 (7.7)             |                  |
| Diagnosis Other autoimmune diseases         | 3 (42.9)     | 4 (57.1)         |                   | 3 (42.9)          | 4 (57.1)            | 0 (0)            |
| Tb infection in the past                    |              |                  |                   |                   |                     |                  |
| No                                         | 41 (27.7)    | 107 (72.3)       | 1.000**           | 105 (70.9)        | 43 (29.1)           | 0.071**          |
| Yes                                        | 3 (30.0)     | 7 (70.0)         |                   | 4 (40.0)          | 6 (60.0)            | 5 (71.4)         |
| Corticosteroids                            |              |                  |                   |                   |                     |                  |
| No                                         | 25 (21.4)    | 92 (78.6)        | 0.002             | 82 (70.1)         | 35 (29.9)           | 0.614            |
| Yes                                        | 19 (46.3)    | 22 (53.7)        |                   | 27 (65.9)         | 14 (34.1)           | 24 (80)          |
| DMARDs                                     |              |                  |                   |                   |                     |                  |
| No                                         | 32 (28.1)    | 82 (71.9)        | 0.920             | 76 (66.7)         | 38 (33.3)           | 0.310            |
| Yes                                        | 12 (27.3)    | 32 (72.7)        |                   | 33 (75)           | 11 (25)             | 28 (87.5)        |
| TNF-α inhibitors                           |              |                  |                   |                   |                     |                  |
| No                                         | 40 (29)      | 98 (71)          | 0.402             | 97 (70.3)         | 41 (29.7)           | 0.352            |
| Yes                                        | 4 (20)       | 16 (80)          |                   | 12 (60)           | 8 (40)              | 15 (100)         |
| Suggestion for preventive treatment for LTBI|              |                  |                   |                   |                     |                  |
| No                                         | 24 (46.2)    | 28 (53.8)        | <0.001            | 39 (75)           | 13 (25)             | 0.058            |
| Yes                                        | 11 (13.3)    | 72 (86.7)        |                   | 49 (59)           | 34 (41)             | 48 (87.3)        |
| Positive TST                               |              |                  |                   |                   |                     |                  |
| No                                         | 44 (100.0)   | 0 (0.0)          | ->                | 40 (90.9)         | 4 (9.1)             | <0.001           |
| Yes                                        | 0 (0.0)      | 114 (100.0)      |                   | 69 (60.5)         | 45 (39.5)           | 70 (87.5)        |
| Positive QFT-GIT                           |              |                  |                   |                   |                     |                  |
| No                                         | 40 (36.7)    | 69 (63.3)        | <0.001            | 109 (100.0)       | 0 (0.0)             | ->               |
| Yes                                        | 4 (8.2)      | 45 (91.8)        |                   | 0 (0.0)           | 49 (100.0)          | 25 (73.5)        |
| BCG                                        |              |                  |                   |                   |                     |                  |
| No                                         | 15 (33.3)    | 30 (66.7)        | 0.104             | 26 (57.8)         | 19 (42.2)           | 0.001            |
| Yes                                        | 13 (19.7)    | 53 (80.3)        |                   | 56 (84.8)         | 10 (15.2)           | 42 (91.3)        |
| Duration of immunosuppressive therapy      |              |                  |                   |                   |                     |                  |
| No therapy                                 | 17 (23.6)    | 55 (76.4)        | 0.402             | 47 (65.3)         | 25 (34.7)           | 0.988            |
| <12 months                                 | 11 (36.7)    | 19 (63.3)        |                   | 20 (66.7)         | 10 (33.3)           | 17 (81.0)        |
| >12 months                                 | 4 (26.7)     | 11 (73.3)        |                   | 10 (66.7)         | 5 (33.3)            | 11 (84.6)        |

*Pearson’s chi-square test **Fisher’s exact test +Not computed due to no distribution
two patients had abnormal chest x-ray and three had received corticosteroids in combination with DMARDs and/or TNF-α therapy in the past for at least 6 months. These findings could be TST false negative due to inhibition of the immune cells relating to the level of immunosuppression (18). Among the 69 TST(+)/QFT-GIT(+) cases of discordance, TST’s potential positive results could in part be explained by a younger age (mean age of 69 cases 42 years old) and cross reaction with BCG vaccine strains (n=44) in a country with a previously high rate of infection (14, 17). Moreover, Nienhaus and colleague (18) connected TST(+) results with receiving BCG vaccination after infancy and birthplace in a country with high TB incidence. Further the observed QFT-GIT (−) results could be false negative due to the use of immunosuppressive drugs which directly reduce the production of cytokines such as INF-γ and TNF-α from T cells (19). QFT-GIT vs. TST agreement was found to be lower than expected by the study authors, as almost perfect agreement (k=0.81-1.00), substantial (k=0.61-0.80), moderate (k=0.41-0.60) as moderate, 0.61-0.80 as substantial, and 0.81-1.00 as almost perfect agreement.

Limitations: In any setting where records are reviewed retrospectively, it is not always possible to collect the same data for every patient. Items such as “dose” and “duration of use” were not available in every chart, neither was there information regarding patient compliance with previous treatment of autoimmune disease. While these would have been interesting, and allowed for a more in-depth look into the topic, it that indeterminate results were associated with older age and immunosuppressive therapy. On the contrary researchers from Italy (25), a low TB endemic country with a low BCG immunization rate, performed the two tests in 398 patients with autoimmune diseases and found a smaller rate of indeterminate results (1.2%) supporting that their findings confirms the accuracy of QFT-GIT in autoimmune patients who have been under immunosuppressive therapy in the past.

Age was found to be an aggravating factor for the QFT-GIT(+) and abnormal chest x-ray results, and correlated positively in the multiple logistic regression, in accordance with other studies (26). When considering LTBI, early detection and proper treatment are the priorities to control the disease and reduce the risk of progression to active disease in patients with autoimmune diseases. Strategies for the investigation of LTBI have small differences between USA, European countries and Australia, (10,27-29) but still it is unclear which is best. Taking into account at least one risk factor for LTBI such as TST(+) with cut-off point ≥ 5 mm (n=114, 72.1%), or QFT-GIT(+) (n=49, 31.0%) and chest x-ray findings of prior TB (n=17, 15.9 %.), only TST(+) patients are recommended chemoprophylaxis for LTBI. However if we identify latency by confirmed TST(+) and QFT-GIT(+) (n=45) then fewer patients would have been administrated chemoprophylaxis. However, because TB will develop among patients who have been infected with MTB, and because currently there isn’t a gold standard method to distinguish the latent from active infection, the clinician should consider offering preventive chemoprophylaxis in patients with autoimmune diseases testing positive on either of the two tests (30).

### Table 5. Results of multiple logistic regression to investigate factors associated with positive TST, positive QFT-GIT and chest x-ray. *indicates reference category ‡Odds Ratio (95% Confidence Interval)
was felt that the level of information available in the patient charts was enough to provide useful, representative data.

6. CONCLUSION

QFT-GIT is more sensitive than TST in patients under immunosuppressive therapy, but TST detects more cases of LTBI. TST remains an inexpensive test worldwide, which does not need laboratory equipment. Additionally, neither of the two methods distinguish latent from active TB, and neither one is better at recognizing patients with autoimmune diseases who could avail from preventive chemoprophylaxis. Since the literature for the economic evaluation of LTBI screening has not clearly defined which test is ultimately more cost-effective, low income countries like Greece should continue using TST as the primary method for diagnosis of LTBI.

REFERENCES

1. World Health Organization (WHO). Guidelines on the Management of Latent Tuberculosis Infection. Geneva, World Health Organization. http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908_eng.pdf?ua=1&amp;ua=1;2015 [Access: October 17, 2017]
2. Wallis RS. Tumor necrosis factor antagonists: structure, function and tuberculosis risks. Lancet Infect Dis. 2008; 8: 601-11.
3. Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatananobodee P, et al. Risk of tuberculosis with anti-tumor necrosis factor-a therapy: substantially higher number of patients at risk in Asia. International Journal of Rheumatic Diseases. 2014; 17: 291-8.
4. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira RM, et al. I. The evaluation of latent tuberculosis infection: an Updated Review. Ann Clin Lab Science. 2010; 35(3): 69-84.
5. Pai M, Kalantari S, Dheka K. New tools and emerging technologies for the diagnosis of tuberculosis Part I. Latent tuberculosis. Expert Review of Molecular Diagnostics. 2006; 6(3): 413-22.
6. Moon HW, Har M. Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection: an Updated Review. Ann Clin Lab Science. 2013; 43(2): 221-9.
7. Centers for Disease Control and Prevention (CDC). Tuberculin Skin Testing. https://www.cdc.gov/tb/publications/factsheets/testing/skin-testing.pdf [Access: October 17, 2017].
8. Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States-MMWR. 2010; 59(RR05).
9. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremers JM et al. 2012. Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2012; 64(3): 625-39.
10. Chapman HJ, Lauizzo MJ. Advances in Diagnosis and Treatment of Latent Tuberculosis Infection. Am Board Fam Med. 2014; 27(3): 704-12.
11. Bouros D, Demoliopoulos J, Panagou P, Yiotaomanolakis N, Moschos M, Paraskevopoulos A, et al. Incidence of Tuberculosis in Greek Armed Forces from 1965-1993. Respiratio. 1995; 62: 336-40.
12. World Health Organization Europe. Highlights on health in Greece 2004. http://www.euro.who.int/__data/assets/pdf_file/0008/103220/GRE_Highlights.pdf [Access: October 26, 2017].
13. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006; 10(11): 192-204.
14. Wang L, Turner MO, Elwood KK. A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax. 2002; 57(9): 804-9.
15. Aleti N, Domínguez J, Souza-Galvão ML, Jiménez-Fuentes MA, Milé C, Soloms J, et al. Predicting the Development of Tuberculosis with the Tuberculin Skin Test and QuantiFERON®. Ann Am Thorac Soc. 2015; 12(3): 680-8.
16. Weinfurter P, Blumberg H, Goldbaum G, Royce R, Pang J, Tapia J, et al. Tuberculosis Epidemiological Studies Consortium. Author information. Predictors of discordant tuberculin skin test and QuantiFERON®-TB Gold In-Tube results in various high-risk groups. Int J Tuberc Lung Dis. 2011; 15(8): 1056-61.
17. Nienhaus A, Schahlon A, Diel R. Interferon-Gamma Release Assay for the Diagnosis of Latent TB Infection- Analysis of Discordant Results, when compared to the Tuberculin Skin Test. PLoS ONE. 2008; 3(7): e2665.
18. Nzidi E, Nguefeu C, Nkenfou, Gwom L, Fainguem N, Fokam J et al. The pros and cons of the QuantiFERON® test for the diagnosis of tuberculosis, prediction of disease progression, and treatment monitoring. International Journal of Mycobacteriology. 2016; 5(2): 177-84.
19. Lee JH, Sohn HS, Chun JH, Kim HA, Suh CH, Lee YW, et al. Poor agreement between QuantiFERON-TB Gold test and tuberculin skin test results for the diagnosis of latent tuberculosis infection in rheumatoid arthritis patients and healthy controls. Korean J Intern Med. 2014; 29: 1.
20. Ponce de Leon D, Acevedo-Vasquez E, Alivizursi S, Gutierrez C, Cacho M, Alfaro J, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol. 2008; 35(5): 776-81.
21. Kleinert S, Kurzai O, Elias J, Marten K, Engelke C, et al. Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2010; 69(7): 782-4.
22. Spala G, Athanasious M. Epidemiological data on tuberculosis in Greece, 2004–2010. Office for Airborne Diseases. HDCP NEWSLETTER. http://www.keelmpo.gr/Portals/o/Newsletter/HDCP_NEWSLETTER_MARCH_2011.pdf [Access: October 23, 2017].
23. Kobashi Y, Sugiu T, Mouri K, Ohashi Y, Miyashita N, Oka M. Indeterminate Results of QuantiFERON®-TB Gold test performed in routine clinical practice. European Respiratory Journal. 2009; 33(6): 812-5.
24. Bartalesi F, Visidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. European Respiratory Journal. 2009; 33: 856-93.
25. Vasilopoulos D, Tsirikliki S, Hatara C, Podia V, Randilli A, Stamoulis N, et al. Comparison of two gamma interferon release assays and tuberculin skin testing for the diagnosis of latent tuberculosis infection in a Cohort of Patients with Rheumatic Diseases Starting Anti-Tumor Necrosis Factor Therapy. Clinical Respiratory Journal. 2009; 33: 215-20.
26. Vasilopoulos D, Tsirikliki S, Hatara C, Podia V, Randilli A, Stamoulis N, et al. Comparison of two gamma interferon release assays and tuberculin skin testing for the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol. 2008; 35(5): 776-81.
27. British Thoracic Society (BTS). BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-a treatment. Thorax. 2005; 60: 800-5.
28. Australian Rheumatology association screening for latent tuberculosis infection (LTBI). Prior to use of biological agents in Australia. http://www.rheumatology.org.au/downloads/April2010-FINAL; 2010 [Access: September 17, 2018].
29. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumor necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010; 36: 185-206.
30. Sauzullo I, Vullo V, Mastroianni CM. Detecting latent tuberculosis in compromised Patients. Curr Opin Infect Dis. 2015; 28(3): 275-82.

Mater Sociomed. 2018 Feb; 30(1): 32-37 • ORIGINAL PAPER